Acute Intracerebral Hemorrhage – Zeenat Qureshi Stroke Institute CLUTCH
Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.
The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.
Inclusion Criteria
- Age 18 years or older and less than 100 years.
- Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset.
- Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision, or neglect.
- Initial National Institutes of Health Stroke Scale (NIHSS) score of 1 or greater.
- Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment
- Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement >5 cc (excluding microhemorrhages)
- Other criteria applies
Complete the form to get connected with new research studies and our team will reach out soon to help determine your eligibility.
